239 related articles for article (PubMed ID: 10979858)
41. Bacteria in the pathogenesis of inflammatory bowel disease.
Subramanian S; Campbell BJ; Rhodes JM
Curr Opin Infect Dis; 2006 Oct; 19(5):475-84. PubMed ID: 16940872
[TBL] [Abstract][Full Text] [Related]
42. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
43. Prebiotics in inflammatory bowel diseases.
Guarner F
Br J Nutr; 2007 Oct; 98 Suppl 1():S85-9. PubMed ID: 17922967
[TBL] [Abstract][Full Text] [Related]
44. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
Kugathasan S; Saubermann LJ; Smith L; Kou D; Itoh J; Binion DG; Levine AD; Blumberg RS; Fiocchi C
Gut; 2007 Dec; 56(12):1696-705. PubMed ID: 17682002
[TBL] [Abstract][Full Text] [Related]
45. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
[TBL] [Abstract][Full Text] [Related]
46. Lactococcus lactis, a tool for the delivery of therapeutic proteins treatment of IBD.
Steidler L
ScientificWorldJournal; 2001 May; 1():216-7. PubMed ID: 12805677
[TBL] [Abstract][Full Text] [Related]
47. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice.
Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T
Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030
[TBL] [Abstract][Full Text] [Related]
48. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria?
Blum S; Schiffrin EJ
Curr Issues Intest Microbiol; 2003 Sep; 4(2):53-60. PubMed ID: 14503689
[TBL] [Abstract][Full Text] [Related]
49. In situ delivery of therapeutic cytokines by genetically engineered Lactococcus lactis.
Steidler L
Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet; 2001; 66(3b):551, 553-6. PubMed ID: 15954652
[No Abstract] [Full Text] [Related]
50. Effect of probiotics on intestinal barrier function.
Mennigen R; Bruewer M
Ann N Y Acad Sci; 2009 May; 1165():183-9. PubMed ID: 19538305
[TBL] [Abstract][Full Text] [Related]
51. Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down?
Fantini MC; Monteleone G
Inflamm Bowel Dis; 2017 Oct; 23(10):1682-1688. PubMed ID: 28906289
[TBL] [Abstract][Full Text] [Related]
52. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice.
Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M
Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697
[TBL] [Abstract][Full Text] [Related]
53. Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization.
Li HS; Piao DC; Jiang T; Bok JD; Cho CS; Lee YS; Kang SK; Choi YJ
Vaccine; 2015 Apr; 33(16):1959-67. PubMed ID: 25738814
[TBL] [Abstract][Full Text] [Related]
54. Health, probiotics, and inflammation.
Mengheri E
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S177-8. PubMed ID: 18685508
[TBL] [Abstract][Full Text] [Related]
55. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.
Wang ZK; Yang YS; Chen Y; Yuan J; Sun G; Peng LH
World J Gastroenterol; 2014 Oct; 20(40):14805-20. PubMed ID: 25356041
[TBL] [Abstract][Full Text] [Related]
56. Is there a role for defensins in IBD?
Wehkamp J; Stange EF
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S85-7. PubMed ID: 18816709
[No Abstract] [Full Text] [Related]
57. Mathematical model of the roles of T cells in inflammatory bowel disease.
Lo WC; Arsenescu RI; Friedman A
Bull Math Biol; 2013 Sep; 75(9):1417-33. PubMed ID: 23760658
[TBL] [Abstract][Full Text] [Related]
58. Promotion of a favorable gut flora in inflammatory bowel disease.
Kennedy RJ; Kirk SJ; Gardiner KR
JPEN J Parenter Enteral Nutr; 2000; 24(3):189-95. PubMed ID: 10850949
[TBL] [Abstract][Full Text] [Related]
59. Microbiological and immunological strategies for treatment of inflammatory bowel disease.
Steidler L
Microbes Infect; 2001 Nov; 3(13):1157-66. PubMed ID: 11709296
[TBL] [Abstract][Full Text] [Related]
60. Resident bacterial flora and immune system.
Biancone L; Monteleone I; Del Vecchio Blanco G; Vavassori P; Pallone F
Dig Liver Dis; 2002 Sep; 34 Suppl 2():S37-43. PubMed ID: 12408438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
